Glucocorticoid enhances hypoxia- and/or transforming growth factor-β-induced plasminogen activator inhibitor-1 production in human proximal renal tubular cells

Clinical and Experimental Nephrology

Volumn 15, Issue 1, 2011, Pages 34-40

  Kimura, Hideki ^a   Li, Xuan ^a   Torii, Kunio ^b   Okada, Toshiharu ^b   Kamiyama, Kazuko ^a   Mikami, Daisuke ^a   Kasuno, Kenji ^a   Takahashi, Naoki ^a   Yoshida, Haruyoshi ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b UNIVERSITY OF FUKUI HOSPITAL   (Japan)

Author keywords

Glucocorticoid; Human proximal renal tubular cells; Hypoxia; PAI 1; TGF

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; MESSENGER RNA; MIFEPRISTONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CELL HYPOXIA; CELL LEVEL; CONTROLLED STUDY; DNA STRUCTURE; EXPRESSION VECTOR; GENE ACTIVITY; GENE EXPRESSION; GENETIC TRANSFECTION; GLUCOCORTICOID RESPONSE ELEMENT; HUMAN; HUMAN CELL; HYPOXIA RESPONSE ELEMENT; KIDNEY PROXIMAL TUBULE; PROTEIN SYNTHESIS REGULATION; RNA SYNTHESIS; STEROID ANALYSIS;

ANOXIA; CELLS, CULTURED; DEXAMETHASONE; GLUCOCORTICOIDS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY TUBULES, PROXIMAL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN-TYROSINE KINASES; RECEPTORS, GLUCOCORTICOID; TRANSFORMING GROWTH FACTOR BETA1;

EID: 79952193645     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-010-0351-7     Document Type: Article

References (27)

1. MJ Schaaf JA Cidlowski 2002 Molecular mechanisms of glucocorticoid action and resistance J Steroid Biochem Mol Biol 83 37 48 1:CAS:528: DC%2BD3sXitFahsrw%3D 10.1016/S0960-0760(02)00263-7 12650700 (Pubitemid 37040640)
2. O Kassel P Herrlich 2007 Crosstalk between the glucocorticoid receptor and other transcription factors: molecular aspects Mol Cell Endocrinol 275 13 29 1:CAS:528:DC%2BD2sXpt1Sktbw%3D 10.1016/j.mce.2007.07.003 17689856 (Pubitemid 47259283)
3. G Neeck R Renkawitz M Eggert 2002 Molecular aspects of glucocorticoid hormone action in rheumatoid arthritis Cytokines Cell Mol Ther 7 61 69 1:CAS:528:DC%2BD3sXhvVyqtrc%3D 10.1080/13684730412331302081 12607796 (Pubitemid 36187839)
4. C Ponticelli 2006 New therapies for lupus nephritis Clin J Am Soc Nephrol 1 863 868 1:CAS:528:DC%2BD28XnsVWiu7c%3D 10.2215/CJN.00880306 17699298
5. WG Couser 1999 Glomerulonephritis Lancet 353 1509 1515 1:STN:280:DyaK1M3kslaqsQ%3D%3D 10.1016/S0140-6736(98)06195-9 10232333 (Pubitemid 29204381)
6. JE Balow HA Austin 3rd LR Muenz KM Joyce TT Antonovych JH Klippel, et al. 1984 Effect of treatment on the evolution of renal abnormalities in lupus nephritis N Engl J Med 311 491 495 1:STN:280:DyaL2c3ntVGlsA%3D%3D 10.1056/NEJM198408233110802 6749206 (Pubitemid 14059349)
7. HA Austin 3rd JH Klippel JE Balow NG le Riche AD Steinberg PH Plotz, et al. 1986 Therapy of lupus nephritis controlled trial of prednisone and cytotoxic drugs N Engl J Med 314 614 619 10.1056/NEJM198603063141004 3511372 (Pubitemid 16132725)
8. N Yoshikawa M Honda K Iijima M Awazu S Hattori K Nakanishi, et al. 2006 Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial Clin J Am Soc Nephrol 1 511 517 1:CAS:528:DC%2BD28Xlt1Kls7s%3D 10.2215/CJN.01120905 17699253
9. Y Kobayashi K Fujii Y Hiki S Tateno A Kurokawa M Kamiyama 1988 Steroid therapy in IgA nephropathy: a retrospective study in heavy proteinuric cases Nephron 48 12 17 1:STN:280:DyaL1c7it1ylsg%3D%3D 10.1159/000184861 3340251 (Pubitemid 18019324)
10. M Sato O Hotta S Tomioka I Horigome S Chiba M Miyazaki, et al. 2003 Cohort study of advanced IgA nephropathy: efficacy and limitations of corticosteroids with tonsillectomy Nephron Clin Pract 93 c137 c145 1:CAS:528:DC%2BD3sXktFSmsrg%3D 10.1159/000070233 12759582
11. M Nangaku 2006 Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure J Am Soc Nephrol 17 17 25 1:CAS:528:DC%2BD28XhtFyqtbY%3D 10.1681/ASN.2005070757 16291837
12. JT Norman LG Fine 2006 Intrarenal oxygenation in chronic renal failure Clin Exp Pharmacol Physiol 33 989 996 1:CAS:528:DC%2BD28XhtFWqsbnL 10.1111/j.1440-1681.2006.04476.x 17002678 (Pubitemid 44427323)
13. GL Semenza 2000 HIF-1: mediator of physiological and pathophysiological responses to hypoxia J Appl Physiol 88 1474 1480 1:CAS:528:DC%2BD3cXivF2ku74%3D 10749844 (Pubitemid 30217451)
14. MO Leonard C Godson HR Brady CT Taylor 2005 Potentiation of glucocorticoid activity in hypoxia through induction of the glucocorticoid receptor J Immunol 174 2250 2257 1:CAS:528:DC%2BD2MXhtV2rtrY%3D 15699159 (Pubitemid 40223972)
15. CD Heiniger RM Kostadinova MK Rochat A Serra P Ferrari B Dick, et al. 2003 Hypoxia causes down-regulation of 11 beta-hydroxysteroid dehydrogenase type 2 by induction of Egr-1 Faseb J 17 917 919 1:CAS:528:DC%2BD3sXjsFantbc%3D 12626438
16. X Li H Kimura K Hirota K Kasuno K Torii T Okada, et al. 2005 Synergistic effect of hypoxia and TNF-alpha on production of PAI-1 in human proximal renal tubular cells Kidney Int 68 569 583 1:CAS:528:DC%2BD2MXpt1Wmsb8%3D 10.1111/j.1523-1755.2005.00435.x 16014034 (Pubitemid 43323112)
17. JP Rerolle A Hertig G Nguyen JD Sraer EP Rondeau 2000 Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis Kidney Int 58 1841 1850 1:CAS:528:DC%2BD3cXotV2isr0%3D 10.1111/j.1523-1755.2000.00355.x 11044203
18. AA Eddy AB Fogo 2006 Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action J Am Soc Nephrol 17 2999 3012 1:CAS:528:DC%2BD28Xht1yjtb3K 10.1681/ASN.2006050503 17035608 (Pubitemid 44707760)
19. Strutz F, Müller GA. Mechanism of renal fibrogenesis. In: Neilson EG, editor. Immnonologic renal diseases. 2nd ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 73-101.
20. JJ Kanalas U Hopfer 1997 Effect of TGF-beta 1 and TNF-alpha on the plasminogen system of rat proximal tubular epithelial cells J Am Soc Nephrol 8 184 192 1:CAS:528:DyaK2sXhvV2hurg%3D 9048336 (Pubitemid 127455872)
21. H Kimura X Li K Torii T Okada K Kamiyama D Mikami, et al. 2009 Dexamethasone enhances basal and TNF-α-stimulated production of PAI-1 via the glucocorticoid receptor regardless of 11β-hydroxysteroid dehydrogenase 2 status in human proximal renal tubular cells Nephrol Dial Transpl 24 1759 1765 1:CAS:528:DC%2BD1MXmtlOgtbo%3D 10.1093/ndt/gfn756
22. T Oda YO Jung HS Kim X Cai JM Lopez-Guisa Y Ikeda, et al. 2001 PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction Kidney Int 60 587 596 1:CAS:528:DC%2BD3MXmtVOntrg%3D 10.1046/j.1523-1755.2001.030002587.x 11473641 (Pubitemid 32678902)
23. SB Nicholas E Aguiniga Y Ren J Kim J Wong N Govindarajan, et al. 2005 Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy Kidney Int 67 1297 1307 1:CAS:528:DC%2BD2MXjsV2mur0%3D 10.1111/j.1523-1755.2005.00207. x 15780082 (Pubitemid 40463106)
24. MC Marchetti B Di Marco G Cifone G Migliorati C Riccardi 2003 Dexamethasone-induced apoptosis of thymocytes: role of glucocorticoid receptor-associated Src kinase and caspase-8 activation Blood 101 585 593 1:CAS:528:DC%2BD3sXkvVWrug%3D%3D 10.1182/blood-2002-06-1779 12393559 (Pubitemid 36077581)
25. T Fink A Kazlauskas L Poellinger P Ebbesen V Zachar 2002 Identification of a tightly regulated hypoxia-response element in the promoter of human plasminogen activator inhibitor-1 Blood 99 2077 2083 1:CAS:528: DC%2BD38XitF2ntbk%3D 10.1182/blood.V99.6.2077 11877282 (Pubitemid 34525491)
26. H Derendorf H Mollmann J Barth C Mollmann S Tunn M Krieg 1991 Pharmacokinetics and oral bioavailability of hydrocortisone J Clin Pharmacol 31 473 476 1:STN:280:DyaK3M3mvVarsg%3D%3D 2050835
27. DE Duggan KC Yeh N Matalia CA Ditzler FG McMahon 1975 Bioavailability of oral dexamethasone Clin Pharmacol Ther 18 205 209 1:CAS:528:DyaE2MXltlKrsbk%3D 1097154